Loading...
•
Mar 31, 2024
Edwards Lifesciences Q1 2024 Earnings Report
Edwards Lifesciences reported a 10% increase in sales, driven by growth in TAVR and TMTT, and raised its 2024 sales guidance.
Key Takeaways
Edwards Lifesciences reported strong first-quarter results, with sales growing 10% to $1.6 billion and adjusted EPS of $0.66. The company has raised its full-year 2024 sales guidance due to this encouraging start of the year.
Q1 sales grew 10% on a reported and constant currency basis to $1.6 billion.
Q1 TAVR sales grew 6%, or 8% on a constant currency basis adjusted for billing days, driven by growth in the U.S. and Japan.
Q1 TMTT sales grew 75%, driven by expanded adoption and new site activation of PASCAL.
The company is raising its 2024 sales guidance to the high end of the previous 8 to 10% range.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Edwards Lifesciences expects full-year 2024 sales growth to be at the high end of the prior guidance of 8 to 10% and $6.3 to $6.6 billion. For the second quarter of 2024, the company projects total sales to be between $1.62 and $1.70 billion, and adjusted EPS of $0.67 to $0.71.
Positive Outlook
- Full-year 2024 sales growth is expected to be at the high end of the prior guidance of 8 to 10%.
- The company remains confident in TAVR sales growth of 8 to 10% on a constant currency basis.
- Full-year Surgical Structural Heart sales growth is expected to be 6 to 8%.
- Full-year Critical Care sales growth is expected to be 8 to 10%.
- Full-year TMTT sales are now expected to be in a range of $320 to $340 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...